561 related articles for article (PubMed ID: 35551655)
21. Engineering Opportunities in Cancer Immunotherapy: After Decades of Missteps and Delays, a Growing Immune-Oncology Market and Improved Cancer Treatment Outcomes Open New Prospects for Biomedical Engineers and Data Scientists.
Zaharoff DA
IEEE Pulse; 2018; 9(4):8-11. PubMed ID: 30028678
[TBL] [Abstract][Full Text] [Related]
22. Combining immunotherapies for the treatment of prostate cancer.
Redman JM; Gulley JL; Madan RA
Urol Oncol; 2017 Dec; 35(12):694-700. PubMed ID: 29146441
[TBL] [Abstract][Full Text] [Related]
23. Precision Medicine-Enabled Cancer Immunotherapy.
Lee JK; Priceman SJ
Cancer Treat Res; 2019; 178():189-205. PubMed ID: 31209846
[TBL] [Abstract][Full Text] [Related]
24. Is There a Role for Immunotherapy in Prostate Cancer?
Rizzo A; Mollica V; Cimadamore A; Santoni M; Scarpelli M; Giunchi F; Cheng L; Lopez-Beltran A; Fiorentino M; Montironi R; Massari F
Cells; 2020 Sep; 9(9):. PubMed ID: 32911806
[TBL] [Abstract][Full Text] [Related]
25. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
26. Current status of immunological approaches for the treatment of prostate cancer.
Drake CG; Antonarakis ES
Curr Opin Urol; 2012 May; 22(3):197-202. PubMed ID: 22328018
[TBL] [Abstract][Full Text] [Related]
27. A comprehensive review of immunotherapies in prostate cancer.
Maia MC; Hansen AR
Crit Rev Oncol Hematol; 2017 May; 113():292-303. PubMed ID: 28427519
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
29. Cellular immunotherapies for prostate cancer.
McNeel DG
Biomed Pharmacother; 2007 Jul; 61(6):315-22. PubMed ID: 17306498
[TBL] [Abstract][Full Text] [Related]
30. Prostate cancer vaccines: current status.
Hwang LC; Fein S; Levitsky H; Nelson WG
Semin Oncol; 1999 Apr; 26(2):192-201. PubMed ID: 10597730
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy to Treat Cancer.
McCune JS
Clin Pharmacol Ther; 2016 Sep; 100(3):198-203. PubMed ID: 27513619
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapies and Combination Strategies for Immuno-Oncology.
Barbari C; Fontaine T; Parajuli P; Lamichhane N; Jakubski S; Lamichhane P; Deshmukh RR
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679922
[TBL] [Abstract][Full Text] [Related]
33. Immunodiagnostics and Immunotherapy Possibilities for Prostate Cancer.
Schatten H
Adv Exp Med Biol; 2018; 1096():185-194. PubMed ID: 30324354
[TBL] [Abstract][Full Text] [Related]
34. Current status of immunological therapies for prostate cancer.
Antonarakis ES; Drake CG
Curr Opin Urol; 2010 May; 20(3):241-6. PubMed ID: 20179598
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy for prostate cancer: recent developments and future challenges.
Schweizer MT; Drake CG
Cancer Metastasis Rev; 2014 Sep; 33(2-3):641-55. PubMed ID: 24477411
[TBL] [Abstract][Full Text] [Related]
36. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
37. Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.
Gardner TA; Elzey BD; Hahn NM
Hum Vaccin Immunother; 2012 Apr; 8(4):534-9. PubMed ID: 22832254
[TBL] [Abstract][Full Text] [Related]
38. Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
Dawson NA; Roesch EE
Expert Opin Biol Ther; 2014 May; 14(5):709-19. PubMed ID: 24620782
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
Sun BL
Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
[TBL] [Abstract][Full Text] [Related]
40. Clinical development of immunotherapy for prostate cancer.
Noguchi M; Koga N; Igawa T; Itoh K
Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
